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Abstract: Melanoma treatment has been revolutionized over the past decade. Long-term results with
immuno-oncology (I-O) agents and targeted therapies are providing evidence of durable survival for a sub-
stantial number of patients. These results have prompted consideration of how best to define long-term
benefit and cure. Now more than ever, oncologists should be aware of the long-term outcomes demon-
strated with these newer agents and their relevance to treatment decision-making. As the first tumor type
for which I-O agents were approved, melanoma has served as a model for other diseases. Accordingly,
discussions regarding the value and impact of long-term survival data in patients with melanoma may be
relevant in the future to other tumor types. Current findings indicate that, depending on the treatment,
over 50% of patients with melanoma may gain durable survival benefit. The best survival outcomes
are generally observed in patients with favorable prognostic factors, particularly normal baseline lactate
dehydrogenase and/or a low volume of disease. Survival curves from melanoma clinical studies show a
plateau at 3 to 4 years, suggesting that patients who are alive at the 3-year landmark (especially in cases
in which treatment had been stopped) will likely experience prolonged cancer remission. Quality-of-life
and mixture-cure modeling data, as well as metrics such as treatment-free survival, are helping to de-
fine the value of this long-term survival. In this review, we describe the current treatment landscape
for melanoma and discuss the long-term survival data with immunotherapies and targeted therapies,
discussing how to best evaluate the value of long-term survival. We propose that some patients might
be considered functionally cured if they have responded to treatment and remained treatment-free for
at least 2 years without disease progression. Finally, we consider that, while there have been major
advances in the treatment of melanoma in the past decade, there remains a need to improve outcomes
for the patients with melanoma who do not experience durable survival.
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ABSTRACT
Melanoma treatment has been revolutionized over the 
past decade. Long- term results with immuno- oncology 
(I- O) agents and targeted therapies are providing 
evidence of durable survival for a substantial number 
of patients. These results have prompted consideration 
of how best to define long- term benefit and cure. Now 
more than ever, oncologists should be aware of the long- 
term outcomes demonstrated with these newer agents 
and their relevance to treatment decision- making. 
As the first tumor type for which I- O agents were 
approved, melanoma has served as a model for other 
diseases. Accordingly, discussions regarding the value 
and impact of long- term survival data in patients with 
melanoma may be relevant in the future to other tumor 
types. Current findings indicate that, depending on the 
treatment, over 50% of patients with melanoma may 
gain durable survival benefit. The best survival outcomes 
are generally observed in patients with favorable 
prognostic factors, particularly normal baseline lactate 
dehydrogenase and/or a low volume of disease. Survival 
curves from melanoma clinical studies show a plateau 
at 3 to 4 years, suggesting that patients who are alive 
at the 3- year landmark (especially in cases in which 
treatment had been stopped) will likely experience 
prolonged cancer remission. Quality- of- life and 
mixture- cure modeling data, as well as metrics such as 
treatment- free survival, are helping to define the value 
of this long- term survival. In this review, we describe the 
current treatment landscape for melanoma and discuss 
the long- term survival data with immunotherapies and 
targeted therapies, discussing how to best evaluate 
the value of long- term survival. We propose that some 
patients might be considered functionally cured if they 
have responded to treatment and remained treatment- 
free for at least 2 years without disease progression. 
Finally, we consider that, while there have been major 
advances in the treatment of melanoma in the past 
decade, there remains a need to improve outcomes 
for the patients with melanoma who do not experience 
durable survival.
INTRODUCTION
Despite intensive efforts, the goal of curing 
cancer has proven to be elusive for most 
advanced solid tumors, including mela-
noma. To achieve this goal, an in- depth 
understanding of melanoma biology, tumor 
development, and the body’s innate defense 
against tumor progression is required. 
Advances in our understanding of mela-
noma have facilitated the development and 
subsequent approval of various novel cancer 
therapies with the ability to substantially 
improve outcomes.
Melanoma is the paradigm of how the 
treatment landscape can be revolution-
ized over a decade. Since 2011, a series 
of novel immuno- oncology (I- O) agents, 
targeted therapies, and combination regi-
mens have been approved.1 Robust data 
from phase III trials2–7 and subsequent 
real- world evidence8–10 have unequivocally 
demonstrated overall survival (OS) and 
progression- free survival (PFS) benefits with 
these agents. As the follow- up of pivotal trials 
continues, a substantial body of long- term 
data is emerging that supports the durability 
of survival with some agents.11–17 These data 
are altering practice in ways almost incon-
ceivable a decade ago, raising new clinical 
questions and challenges.
In this review, we consider the current 
treatment landscape for metastatic mela-
noma, including the following questions: 
Are patients with sustained benefit actually 
cured? Can treatment and/or follow- up of 
these patients be safely stopped, allowing 
a return to their lives before diagnosis? 
How is the value of long- term survival best 
assessed, and can these metrics guide treat-
ment choice? Does the demonstration of 
durable outcomes for patients treated in the 
metastatic setting impact the role of local 
or regional therapies? How can outcomes 
be improved for patients with melanoma 
who do not experience durable survival? 
Because melanoma was the first tumor 
type for which I- O agents were approved, it 
has served as a guiding example for other 
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prove to be informative for the treatment of different 
tumor types in the future.
DISCUSSION
The evolution of melanoma treatment
Supported by innovative research tools and techniques, 
our understanding of tumor biology has improved, partic-
ularly in regard to the mechanisms tumors use to escape 
detection by the immune system. Fundamental to greater 
understanding has been the development of the immu-
noediting theory, which describes the interaction between 
the tumor and the immune system as a three- step process 
(referred to as the three Es): (1) elimination of tumors 
at an early stage (also known as the immune surveil-
lance hypothesis); (2) equilibrium (when the immune 
system controls the tumor); and (3) escape (when tumor 
cells are fully immunoedited and grow without immune 
control). The three Es are now accepted as a template for 
understanding the interactions of cancer cells with the 
host immune system.18 This concept has important ther-
apeutic consequences because it implies that fully devel-
oped tumors are inherently immune- resistant. This has 
shifted our therapeutic strategies away from stimulating 
the immune system by vaccination, interleukin (IL)-2, 
or other strategies and toward counteracting immune 
escape mechanisms. The first agents were designed to 
block the inhibitory immune checkpoint receptors cyto-
toxic T- lymphocyte associated antigen-4 (CTLA-4) and 
programmed death 1 (PD-1). CTLA-4 is expressed on 
T cells where it acts to regulate the magnitude of the 
early, priming stages of T- cell activation. Once the T- cell 
receptor binds to an antigen, cluster of differentiation 
(CD)28, a co- stimulatory receptor, amplifies the signal 
to activate the T cells. CD28 and CTLA-4 share ligands 
(CD80 (B7.1) and CD86 (B7.2)), for which CTLA-4 has a 
much greater affinity than CD28. Therefore, expression 
of CTLA-4 on the T- cell surface outcompetes CD28 for 
ligand binding, delivering inhibitory signals to the T cell 
and reducing activation.19 Unlike CTLA-4, the primary 
role of PD-1 is to limit the activity of T cells during the 
effector phase of the immune response in the peripheral 
tissue, limiting autoimmunity. The engagement of PD-1 
by its ligands, programmed death- ligand 1 (PD- L1) and 
PD- L2, results in an inhibitory signal that reduces T- cell 
proliferation, cytotoxicity, and cytokine production.19 
The PD-1 and CTLA-4 pathways are distinct, acting at 
different times and locations to regulate T- cell activa-
tion.20 In tumors, inhibiting these pathways has different 
effects: blocking CTLA-4 induces de novo antitumor 
T- cell responses, while PD-1 inhibition restores antitumor 
T- cell function.19–23 These distinct but potentially comple-
mentary effects led to the clinical evaluation of immune 
checkpoint inhibitor- based combinations.
While immune checkpoint inhibitors are now a mainstay 
of treatment for patients with metastatic melanoma, other 
therapeutic approaches designed to modulate a patient’s 
immune system have also been developed. Adoptive 
cell transfer involves the infusion of autologous tumor- 
infiltrating lymphocytes that have been expanded in vitro 
with IL-2.24 Development of this approach began in the 
1980s and responses of long duration were first achieved 
with the use of lymphoid depletion prior to adoptive cell 
transfer.25 26 Subsequently, various regimens and production 
processes have subsequently been evaluated in larger clin-
ical trials. Findings from a recent meta- analysis showed that, 
especially when combined with high- dose IL-2, adoptive 
cell transfer achieves durable clinical benefit in a substan-
tial minority of patients; however, the complex production 
process means that this approach is currently used in a 
small, but expanding number of treatment centers world-
wide.24 Vaccination is a strategy to expand tumor- directed 
lymphocytes in vivo. Melanoma vaccines have a long history, 
with numerous approaches having been investigated: the 
majority of studies have evaluated melanoma vaccines used 
alone and have not demonstrated clinical efficacy.27–30 In 
2015, talimogene laherparepvec (TVEC), an oncolytic 
virotherapy, was approved by the US Food and Drug Admin-
istration (FDA) for the local treatment of unresectable 
lesions in patients with melanoma recurrence after initial 
surgery (figure 1).31 32 It has been speculated that the pres-
ence of this genetically modified virus in the melanoma cells 
Figure 1 US Food and Drug Administration approval of 
melanoma therapies.31 32 Agents shown are approved for 
metastatic melanoma unless stated and italicized. aFor 
patients whose tumors express BRAF V600E or V600K. bFor 
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results in an individualized vaccine. Approval was based on 
the results of a randomized phase III trial showing signifi-
cantly improved durable response rates with TVEC versus 
subcutaneous granulocyte- macrophage colony- stimulating 
factor in patients with unresectable stage IIIB to stage IV 
melanoma.33 The final analysis from this trial showed a 33% 
OS rate at 5 years.34 A number of other vaccines are under 
evaluation for the treatment of melanoma and may play 
a role in combination therapy with immune checkpoint 
inhibitors and/or targeted therapies in the future.35
At the same time while research into immune checkpoint 
receptors was being pursued, various tumorigenic muta-
tions were discovered. In particular, BRAF- activating muta-
tions were identified in more than 50% of melanomas and 
found to play a critical role in driving tumor growth and 
development. This led to the development of vemurafenib, 
dabrafenib, and encorafenib which target oncogenic acti-
vating mutations in the MAP kinase (MAPK) pathway, and 
trametinib, cobimetinib, and binimetinib, which target 
MEK.31 36 Clinical experience has demonstrated that the 
majority of patients treated with a BRAF inhibitor alone 
developed resistant disease, primarily involving reactiva-
tion of the MAPK pathway.3 Some patients also developed 
secondary malignancies, such as cutaneous squamous- 
cell carcinoma, attributed to paradoxical BRAF- inhibitor- 
induced activation of the MAPK pathway in RAS- mutant 
tumors. Further research has shown that combined BRAF 
and MEK inhibition delayed the emergence of resistance 
and reduced the incidence of cutaneous hyperproliferative 
lesions compared with single- agent BRAF inhibition, which 
led to the clinical evaluation of combination regimens that 
demonstrated improved therapeutic efficacy compared 
with monotherapy.3
In 2011, the FDA approved the first immune checkpoint 
inhibitor, ipilimumab, and the first targeted therapy, vemu-
rafenib, for melanoma.31 Subsequently, several other agents 
have been approved, based on the demonstration of signif-
icant OS benefit in randomized trials.1 31 These agents were 
initially approved for use as monotherapy (figure 1);31 32 
however, strong scientific and clinical rationale for combi-
nation therapy resulted in the subsequent approval of 
checkpoint- inhibitor- based and targeted therapy- based 
combination regimens. More recently, several adjuvant 
treatments for patients with fully resected stage III or stage 
IV disease have been approved (figure 1).31 37–40
Metastatic melanoma treatment today
The newer therapies for metastatic melanoma have 
undoubtedly improved outcomes for many patients, but 
they have also created new treatment selection challenges 
for both patients and oncologists. This is particularly true 
for patients with BRAF- mutant melanoma, for which both 
I- O agents and targeted therapies are approved.
For patients with BRAF- mutant melanoma, robust data 
have demonstrated a significant benefit for combina-
tion targeted therapy over BRAF- inhibitor monotherapy; 
so, when a targeted therapy is chosen, combination 
BRAF/MEK inhibitor treatment is preferred for most 
patients.3 4 6 7 41 When considering treatment with an I- O 
agent, note that data from randomized trials has clearly 
shown that a PD-1 inhibitor is superior to ipilimumab (a 
CTLA-4 inhibitor) in the first- line setting in terms of both 
efficacy and safety, regardless of tumor BRAF- mutation 
status.2 5 41 42 In the absence of head- to- head studies, the 
choice between the approved PD-1 inhibitors (nivolumab 
or pembrolizumab) is often based on factors such as 
treatment schedule, institutional formulary options, and 
the preference of the treating oncologist. However, as 
long- term data become available, they may also inform 
decision- making (table 1).5 11–17 25 43–46
When deciding whether to prescribe nivolumab plus 
ipilimumab combination therapy or PD-1–inhibitor 
monotherapy, consider that descriptive data from the 
CheckMate 067 trial showed superior median OS with 
the combination versus nivolumab alone (>60 months 
(median not reached) versus 36.9 months; HR 0.83); this 
difference was maintained with up to 5 years of follow- up.12 
The HR for benefit with the combination over nivolumab 
was particularly robust in patients with BRAF- mutant 
disease (0.70; 5- year OS rate 60% vs 46%), elevated (ie, 
two times the upper limit of normal) lactate dehydroge-
nase (LDH; 0.73; 5- year OS rate 28% vs 14%), or M1c 
stage per American Joint Committee on Cancer, seventh 
edition (0.82; 5- year OS rate 43% vs 35%), respectively. 
The frequency and severity of treatment- related adverse 
events (AEs), however, was higher with the combination 
than with nivolumab alone (any grade 96% vs 87%; grade 
3/4 59% vs 23%).12 Consequently, the treatment decision 
is complex and multifactorial, involving careful consider-
ation and discussion about the risks and potential bene-
fits of the treatment options and, in our experience, with 
patient preference often being an important factor.
The choice between I- O and targeted therapy for 
treatment- naive patients with BRAF- mutant disease is 
difficult because of the lack of data from head- to- head 
trials. Most clinicians rely on practical experience, real- 
world and trial data, and expert- opinion publications. 
However, health economic/quality- of- life (QoL) data and 
outcomes from other analyzes, such as data modeling, 
may help to inform decision- making. For example, in 
a recent matching- adjusted indirect comparison, clin-
ical outcomes with nivolumab plus ipilimumab were 
compared with dabrafenib plus trametinib or vemurafenib 
plus cobimetinib combination treatments in patients with 
BRAF- mutant advanced melanoma.47 After adjusting for 
differences in baseline characteristics, PFS and response 
outcomes were similar among the treatments; but, 
beyond 12 months of treatment, nivolumab plus ipili-
mumab improved OS compared with targeted therapy. 
This suggests that the survival benefit with combination 
immunotherapy emerges later and may be more durable 
than with targeted therapies. The incidences of AEs (any- 
grade, grade 3/4) were lowest with dabrafenib plus trame-
tinib (89.5%, 31.6%) and similar between vemurafenib 
plus cobimetinib (97.6%, 59.5%) and nivolumab plus 


































































































































































Table 1 Long- term survival in clinical trials with I- O agents or targeted therapies in patients with advanced/metastatic melanoma
Study Phase Patient population*
Duration of 
survival follow- 













  CheckMate 06712 III Any BRAF 60 (minimum) NIVO+IPI (314),
NIVO 1 mg/kg+IPI 3 mg/kg 
Q3W×4, then NIVO 3 mg/kg 
Q2W
11.5 (8.7 to 19.3) 5 years: 36% NR (38.2 to NR) 5 years: 52%
NIVO (316),
NIVO 3 mg/kg Q2W
6.9 (5.1 to 10.2) 5 years: 29% 36.9 (28.2 to 58.7) 5 years: 44%
IPI (315),
IPI 3 mg/kg Q3W×4
2.9 (2.8 to 3.2) 5 years: 8% 19.9 (16.8 to 24.6) 5 years: 26%
  CheckMate 06616 III BRAF wild- type 60 (minimum) NIVO (210),
NIVO 3 mg/kg Q2W
5.1 (3.5 to 12.2) 5 years: 28% 37.3 (25.4 to 51.6) 5 years: 39%
  KEYNOTE-0065 III Any BRAF
Data shown are for the 
treatment- naive patient 
subgroup
57.7 (median) PEMBRO (368),
PEMBRO 10 mg/kg Q2W/Q3W
11.6 (8.2 to 16.4) 4 years:
26% (Q2W),
28% (Q3W)




IPI 3 mg/kg Q3W×4
3.7 (2.8 to 4.3) NA 17.1 (13.8 to 26.2) NA
  CA184-16944 III Any BRAF 43 (minimum) IPI 10 mg/kg (365), IPI 3 mg/kg 
(362), Q3W×4
2.8 (2.8 to 3.0),
2.8 (2.8 to 2.8)
NA 15.7 (11.6 to 17.8),
11.5 (9.9 to 13.3)
3 years: 31%,
23%
  KEYNOTE-00111 I Any BRAF
Data shown are for the 
treatment- naive patient 
subgroup
55 (median) PEMBRO (151),
PEMBRO 2 mg/kg Q3W/10 mg 
Q2W/10 mg Q3W
16.9 (9.3 to 35.5) 5 years: 29% 38.6 (27.2 to NR) 5 years: 41%
  CA209-00445 I Any BRAF
No prior immune 
checkpoint inhibitor
43.1 (median) NIVO+IPI (94),
Dose- escalation study‡
NA NA NR (40.9 to NR) 4 years: 57%
  CA209-00317 I Previously treated, 
advanced melanoma (any 
BRAF), RCC, or NSCLC 
(only melanoma data 
shown)
58.3 (minimum) NIVO (107),
Dose escalation 0.1 to 10 mg/
kg Q2W
NA NA 20.3 (12.5 to 37.9) 5 years: 34%
  IPI- pooled 
analysis46
II/III Various Approx. 11 
(median)
IPI (1861),
Most patients received 3 or 
10 mg/kg
NA NA 11.4 (10.7 to 12.1) 3 years: 22%
Other immunotherapy
  IL-2 pooled 
analysis19
Various Various 62 (median) High- dose IL-2 (270),
600,000 or 720,000 IU/kg
NA NA 11.4 (NA) NA
Continued



















































Study Phase Patient population*
Duration of 
survival follow- 












  ACT+IL-225 Various Previously treated, 
advanced melanoma
62 (median) Autologous tumor- infiltrating 
lymphocytes+IL-2 after a 
lymphodepletion
NA NA NA 5 years: 29%
Combination- targeted therapy
  COMBI- d and 
COMBI- v15
III BRAF- mutant 22 (median) DAB +TRAM (563),
DAB 150 mg twice daily+TRAM 
2 mg once daily
11.1 (9.5 to 12.8) 5 years: 19% 25.9 (22.6 to 31.5) 5 years: 34%
  COLUMBUS13 III BRAF- mutant 48.8 (median) ENCO+BINI (192),
ENCO 450 mg once daily+BINI 
45 mg twice daily
14.9 (11.0 to 20.2) 3 years: 29% 33.6 (24.4 to 39.2) 3 years: 47%
VEM (191),
VEM 960 mg twice daily
7.3 (5.6 to 7.9) 3 years: 14% 16.9 (14.0 to 24.5) 3 years: 31%
ENCO (194),
ENCO 300 mg once daily
9.6 (7.4 to 14.8) 3 years: 25% 23.5 (19.6 to 33.6) 3 years: 41%
  coBRIM14 III BRAF- mutant NA COBI+VEM (247),
COBI 60 mg once daily+VEM 
960 mg twice daily
12.6 (9.5 to 14.8) 5 years: 14% 22.5 (20.3 to 28.8) 5 years: 31%
VEM (248),
VEM 960 mg twice daily
7.2 (5.6 to 7.5) 5 years: 10% 17.4 (14.5 to 19.8) 5 years: 26%
*Trials were conducted solely in treatment- naive patients unless indicated.
†Data for control arms are only included if ipilimumab or a targeted therapy was the comparator.
‡NIVO+IPI Q3W×4 (mg/kg) in one of the following cohorts: (1) NIVO 0.3+IPI 3; (2) NIVO 1+IPI 3; (2a) NIVO 3+IPI 1; (3) NIVO 3+IPI 3; (8) NIVO 1+IPI 3. Cohorts 1 to 3 received 
maintenance with NIVO Q3W×4, then NIVO+IPI Q12W×8.
ACT, adoptive cell transfer; BINI, binimetinib; COBI, cobimetinib; DAB, dabrafenib; ENCO, encorafenib; IL-2, interleukin-2; I- O, immuno- oncology; IPI, ipilimumab; NA, not available; 
NIVO, nivolumab; NR, not reached; NSCLC, non- small cell lung cancer; OS, overall survival; PEMBRO, pembrolizumab; PFS, progression- free survival; Q2W, every 2 weeks; Q3W, every 
3 weeks; RCC, renal cell carcinoma; TRAM, trametinib; VEM, vemurafenib.
Table 1 Continued
 on December 1, 2020 at Uni of Zurich. Protected by copyright. http://jitc.bmj.com/ J Immunother Cancer: first published as 10.1136/jitc-2020-000948 on 9 October 2020. Downloaded from 
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toxicities is very different between immune checkpoint 
inhibitors and targeted therapies.48
Several randomized trials have been ongoing to 
determine the most effective sequence and administra-
tion of I- O and targeted therapies for all comers and 
biomarker- defined subsets of treatment- naive patients 
with BRAF- mutant melanoma.49–51 The randomized phase 
II SECOMBIT trial (NCT02631447)49 was designed to 
determine the best sequential approach with ipilimumab 
plus nivolumab and encorafenib plus binimetinib. In the 
phase III DREAMseq trial (NCT02224781),50 patients 
will be receiving ipilimumab and nivolumab followed by 
dabrafenib and trametinib or the reverse sequence at the 
time of documented disease progression. The phase II 
EBIN trial (NCT03235245)51 was designed to compare 
encorafenib plus binimetinib followed by nivolumab plus 
ipilimumab versus nivolumab plus ipilimumab. The phase 
II ImmunoCobiVem trial (NCT02902029)52 was designed 
to evaluate cobimetinib plus vemurafenib followed by a 
programmed death ligand 1 (PD- L1) inhibitor.
Long-term survival outcomes
As patients are followed for 5 years and beyond in the 
pivotal trials with I- O agents and targeted therapies, 
long- term data are becoming available and provide 
new metrics that can contribute to treatment decisions. 
Available long- term data are summarized in table 1 and 
figure 2.5 11–17 25 43–46 Because these studies differed in 
their patient populations and other parameters, it is 
not appropriate to compare the trials directly. Addition-
ally, different trial start dates may have impacted the 
patient populations enrolled and the subsequent ther-
apies received. However, when assessing IL-2 or ipilim-
umab treatment, the improvement in clinical outcomes 
in patients treated with PD-1- inhibitor monotherapy, 
targeted therapy, or nivolumab plus ipilimumab becomes 
clear.
Across studies, the best survival outcomes have gener-
ally been observed in patients with favorable prognostic 
factors, particularly a normal or low LDH level and/or 
a low volume of disease. In a pooled survival analysis of 
dabrafenib and trametinib (in patients with BRAF- mutant 
tumors), the 5- year survival rate was 43% in patients with 
LDH at or below the upper limit of normal versus 34% 
in the general population.15 The highest OS rate, 55%, 
was found in patients with low/normal LDH and fewer 
than three sites of disease. In CheckMate 067, there was a 
similar trend for better survival in patients with favorable 
prognostic factors: the highest 5- year survival rates with 
nivolumab plus ipilimumab were observed in patients 
with normal LDH (60%) or normal LDH with fewer than 
three sites of disease (64%), compared with 52% in all 
patients (the 5- year survival rate was 60% for patients with 
BRAF- mutant tumors).12
When long- term data with immune checkpoint inhibi-
tors became available in a pooled analysis of ipilimumab 
trials in which some patients were followed for more than 
10 years,46 attention was drawn to the shape of the OS 
curves, specifically the plateau or flattening of the tail 
of the curve. As shown in figure 2, the immune check-
point inhibitor and IL-2 curves were similar, plateauing 
at 3 or 4 years. The OS curves for targeted therapies 
also appeared to plateau. However, the contributions of 
patients receiving a subsequent therapy were unclear. 
Based on current data, the plateaus for the I- O and the 
targeted agents are expected to be sustained with longer 
follow- up. This leads to the question of whether the 
Dabrafenib+trametinib (phase III) (15)
Nivolumab (phase III) (12)
Ipilimumab 10 mg/kg (phase III) (44)
IL-2 (pooled analysis) (43)
Autologous tumor infiltrating lymphocytes and IL-2 (pooled analysis) (25)
Ipilimumab (phase II and III pooled analysis) (46)
Encorafenib+binimetinib (phase III) (13)
Cobimetinib+vemurafenib (phase III) (14)
Pembrolizumab (phase III) (5)



















Figure 2 Long- term OS in clinical trials with immuno- oncology agents and targeted therapies in patients with advanced 
melanoma. The data presented represent first- line treatment options, with the exception of those for IL-2 and pooled 
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patients represented in the tails of these curves can be 
considered to be functionally cured.
OS curves are known to be impacted by subsequent 
therapies. Many patients treated with BRAF plus MEK 
inhibitor combinations who are still alive may have 
received, or are still receiving, subsequent therapy with 
immune checkpoint inhibitors; patients in immune 
checkpoint inhibitor trials may have received subsequent 
BRAF plus MEK inhibitor combinations. In the pooled 
analysis of the COMBI- d and COMBI- v trials, of the 161 
patients who were alive at 5 years, 72 (45%) had received 
further treatment, the most common being immuno-
therapy (52 patients, 78%).15 In the CheckMate 067 trial, 
of the 281 patients in the nivolumab- containing arms 
who were alive at 5 years, 58 (21%) had received subse-
quent therapy.12 Data were similar for patients with BRAF- 
mutant melanoma: of the 97 patients who were alive at 
5 years, 25 (26%) had received subsequent therapy.53 To 
fully evaluate the contribution of an agent to OS, it may 
be helpful to consider the tail of the PFS curve. PFS offers 
an alternative to OS that is available in a timely manner 
and is not confounded by subsequent therapies or causes 
of mortality unrelated to cancer.54 55 In CheckMate 067 
and the COMBI- d and COMBI- v pooled analyzes, the PFS 
curves appeared to flatten after approximately 3 years. In 
CheckMate 067, PFS rates for the overall population at 3, 
4, and 5 years were 39%, 37%, and 36% with nivolumab 
plus ipilimumab, and 32%, 31%, and 29% with nivolumab 
alone.12 56 57 PFS rates for patients with BRAF- mutant 
melanoma at 3, 4, and 5 years were 40%, 39%, and 38% 
with nivolumab plus ipilimumab, and 22%, 23%, and 
22% with nivolumab alone. In COMBI- d and COMBI- v, 
PFS rates were 24% at 3 years, 21% at 4 years, and 19% at 
5 years.15 In the KEYNOTE-006 trial, PFS rates for patients 
who received either dose of pembrolizumab as a first- line 
therapy declined from 37% at 2 years, to 33% at 3 years, 
and 27% at 4 years; the lack of data beyond 4 years makes 
it unclear whether the curve continued to flatten.5
Defining cure in advanced cancer
Defining cure has not been necessary for most advanced 
cancers. In 1985, Schipper and colleagues proposed the 
term ‘functional cure,’ acknowledging that, given the 
biology of cancer, eradicating all cancer cells or proving 
that they had been eradicated may not be possible, and 
seeking to gain long- term control may be more real-
istic.58 Based on current long- term data, patients could be 
regarded as functionally cured after 3 or 4 years when the 
OS curve plateaus; however, at that time, depending on 
the agent, some patients may still be receiving treatment. 
For example, in CheckMate 067, stopping nivolumab after 
a specific time period had not been mandated and, at 5 
years, 13% of the patients in the nivolumab- containing 
arms who were alive were still receiving study treatment. 
However, the median duration of treatment was short in 
both arms (3.6 months (range, 0.0 to 57.0) with nivolumab 
plus ipilimumab combination therapy and 7.6 months 
(range, 0.0 to 62.9) with nivolumab monotherapy).59 In 
contrast, in the COMBI- d and COMBI- v pooled analysis, 
at 5 years, 43% of the patients who were alive were still on 
study treatment.15 Furthermore, one- half of the patients 
with complete response (CR) on these medications were 
shown to relapse at median of 6.6 months after treatment 
was stopped.60 Findings from a retrospective analysis of 
the long- term outcomes of 396 patients treated with a 
PD-1 inhibitor at a single institution showed that most 
patients discontinued treatment at the time of CR. Most 
CRs were durable, but the probability of treatment failure 
3 years after best overall response was 27%.61
The appropriate time to stop treatment has been the 
subject of much debate, particularly because different 
agents were developed with different stopping rules. For 
example, in the pembrolizumab KEYNOTE-006 trial, 
patients received up to 2 years of treatment5; whereas, in 
the CheckMate 067 trial, patients continued until progres-
sion, unacceptable toxicity, or withdrawal of consent.57 If 
a maximum duration of therapy has not been mandated, 
the decision to stop may be supported by a biopsy showing 
either the absence of viable tumor or negative 18F-2- 
fluoro-2- deoxy- D- glucose- positron emission tomography 
(FDG- PET) imaging. An FDG- PET scan, which provides 
functional information alongside standard anatom-
ical imaging, may help to determine whether residual 
lesions in patients with a partial response (PR) or stable 
disease (SD) contain any viable tumor, thereby identi-
fying patients achieving a complete metabolic response.62 
Results of a study designed to determine whether FDG- 
PET imaging is a better predictor of long- term outcomes 
than a standard CT scan showed that, after 1 year of 
immune checkpoint inhibitor treatment, 28% of patients 
had achieved CR on CT according to Response Evalua-
tion Criteria in Solid Tumors V.1.1.62 In comparison, 
68% of patients with a PR on CT had a complete meta-
bolic response according to FDG- PET imaging. Almost 
all of the patients with a complete metabolic response 
at 1 year had an ongoing response to therapy thereafter. 
Acknowledging that longer follow- up is needed, these 
findings suggest that FDG- PET imaging could help to 
predict long- term survival and guide the decision to stop 
therapy. Other studies are planned to investigate the ideal 
duration of therapy for a specific subset of patients. The 
subject of how long to treat patients requires data, discus-
sion, and development of best- practice guidelines, along 
with the identification of surrogate markers that indicate 
when stopping treatment is safe.
A further consideration is whether a documented radio-
logic CR is necessary for a patient to be considered func-
tionally cured. Given the concept of a functional cure and 
the mechanism of action of I- O agents in particular, the 
long- term absence of progression rather than the docu-
mentation of a CR may be a more appropriate metric. 
Long- term data suggest that achieving a CR is not neces-
sary for a sustained survival benefit, although patients who 
achieve a CR have more durable benefit over time.15 53 63 
In the COMBI- d and COMBI- v pooled analysis, the 5- year 
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with a PR, and 16% in patients with SD.15 In comparison, 
the 5- year OS rates in CheckMate 067 were 90%, 65%, 
and 24% with nivolumab plus ipilimumab combination 
therapy and 93%, 63%, and 40% with nivolumab mono-
therapy.53 Data obtained with pembrolizumab in a pooled 
analysis of KEYNOTE-001 and KEYNOTE-006 showed a 
similar trend, with 4- year OS rates of 98%, 75%, and 66% 
in patients with a CR, PR, or SD at week 24, respectively.64
After taking into consideration both the data above and 
our clinical experience, we propose that patients diag-
nosed with advanced melanoma may be considered func-
tionally cured if they have responded to treatment and 
have been off treatment for at least 2 years without disease 
progression. In our opinion, a patient still receiving treat-
ment cannot be considered functionally cured. Further-
more, while a patient is still on treatment, it cannot be 
determined whether ongoing treatment is necessary to 
control their disease.
Evaluating the value of long-term survival
As these data for melanoma treatments continue to 
mature, landmark survival rates at 5 and 10 years will 
become increasingly relevant. It is also becoming 
important to understand what long- term survival means to 
patients, physicians, payers, and other healthcare profes-
sionals. In this regard, new analytical approaches may 
help to describe long- term survival and inform decision- 
making. Treatment- free survival (TFS) and treatment- 
free interval (TFI) are metrics that may be considered 
alongside traditional efficacy measures. TFS characterizes 
the proportion of time without both treatment or toxicity 
on a particular regimen; it can be further separated into 
time with, and time without treatment- related toxicity of a 
specified grade.65 TFI captures the time interval from the 
last dose of study drug to subsequent systemic therapy.12 
For example, data suggest that TFI positively impacts QoL 
and may improve the cost- effectiveness of immune check-
point inhibitors.66 67 TFI data may help to determine the 
optimal duration of treatment. In CheckMate 067, the 
median TFI for patients receiving nivolumab plus ipili-
mumab combination therapy was 18.1 months compared 
with 1.8 months with nivolumab monotherapy.12 These 
data indicate that a short duration of highly active combi-
nation therapy may be sufficient for many patients to 
achieve durable tumor control without requiring ongoing 
treatment. Additionally, survival at 5 years was similar in 
patients who discontinued combination therapy due to 
AEs during the induction phase and in the overall popu-
lation.12 Emerging data from studies in the neoadjuvant 
setting also suggest that a short course of active therapy 
may be sufficient to achieve durable disease control.68 69
The quality of prolonged survival is a potentially 
important relative determinant of value. The 5- year 
results from CheckMate 067 showed that QoL was main-
tained during the TFI after discontinuation of treatment 
with nivolumab plus ipilimumab combination therapy or 
nivolumab monotherapy.12 Another analysis (Q- TWiST) 
provided evidence that longer quality- adjusted time 
without symptoms or toxicity is attainable for patients 
treated with nivolumab plus ipilimumab than for those 
treated with ipilimumab alone.70 QoL data for patients 
with metastatic melanoma are available from key studies 
with pembrolizumab71 and dabrafenib plus trame-
tinib,72 73 but the analysis period to date is limited to 2 
years after treatment initiation.
For cancer therapies yielding long- term survival and 
hence functional cures in a proportion of patients, tradi-
tional statistical analyzes may not accurately estimate OS 
due to heterogeneity in patient outcomes. Mixture- cure 
models can be used to capture survival heterogeneity 
among patients by assuming that a certain proportion 
of patients are ‘cured’; the mortality risk among these 
patients is considered to be the same as that of the general 
population. Mixture- cure models have been used in 
various cancer settings, including melanoma in the adju-
vant setting, to complement standard survival analyzes. 
By assuming that a proportion of patients in a study 
will never experience an event of interest, these models 
allow a more accurate quantification of the proportion 
of patients who gain a long- term survival benefit (ie, are 
cured).74 75 Determining the ‘cure fraction’ with agents 
in the metastatic setting may provide another valuable 
comparative metric.76 77
Opportunities to improve survival in more patients with 
metastatic melanoma
While some patients achieve long- term survival, 
improving outcomes for those who do not remains an 
important goal (figure 3).78 One approach is to identify 
biomarkers or characteristics that identify the patients 
most likely to achieve long- term survival. Beyond estab-
lished prognostic factors such as baseline LDH and 
disease burden/sites of disease, analyzes of data from key 
phase III studies have failed to identify reliable predic-
tors of poor survival.12 15 79 Analysis of long- term data from 
a phase I study of nivolumab in patients with advanced 
solid tumors, including melanoma, suggested that higher 
absolute lymphocyte count or a higher number of circu-
lating regulatory T cells at baseline was related to survival 
at 5 years, warranting further evaluation.17 Identifying 
predictive biomarkers remains a focus of research; poten-
tial biomarkers under evaluation include tumor muta-
tional burden and neoantigen expression, T- cell receptor 
sequencing, immune- related gene expression, and tumor 
T- cell infiltration.79 Other opportunities to improve long- 
term survival include identifying effective adjuvant treat-
ments for patients with early- stage disease, improving 
the efficacy of adjuvant treatment in high- risk patients 
(perhaps through treatment in the neoadjuvant setting 
or with novel combinations), and the development of 
treatment regimens designed to overcome the innate and 
acquired mechanisms of tumor resistance.
When considering new treatment combinations as a 
way to improve survival, one approach under evaluation 
is the use of I- O plus targeted therapy in patients with 
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that BRAF and MEK inhibitors may impact tumor 
antigen expression, T- cell infiltration, and immune- 
cell populations, making the tumor microenvironment 
more amenable to I- O therapy.80 Several studies are in 
progress, and phase III results are becoming available. 
The phase III IMspire 170 trial (NCT03273153) was 
designed to evaluate atezolizumab (PD- L1 inhibitor) plus 
cobimetinib (MEK inhibitor) versus pembrolizumab in 
untreated patients with BRAF wild- type tumors: unfortu-
nately, it failed to meet its primary endpoint and PFS was 
not improved.81 Recently, positive results were presented 
from a phase III triplet trial, IMspire150 (NCT02908672), 
in which cobimetinib plus vemurafenib was evaluated 
with or without atezolizumab in untreated patients with 
BRAF- mutant melanoma. The triplet combination signifi-
cantly improved PFS compared with cobimetinib plus 
vemurafenib (15.1 vs 10.6 months), although objec-
tive response rates (ORRs) were similar; median OS 
data, although not mature, suggested a benefit with the 
triplet regimen. The safety profile of the triplet combi-
nation was tolerable and manageable.82 In the phase II 
KEYNOTE-022 triplet study of dabrafenib plus trame-
tinib with or without pembrolizumab, the difference in 
median PFS between the arms (16.9 vs 10.7 months) did 
not reach statistical significance. At 24 months, the PFS 
rate was numerically higher in the triplet compared with 
the doublet arm (41% vs 16%), the overall response rate 
was lower (ORR; 63% vs 72%), the duration of response 
was longer (55% vs 16% at 24 months), and there was 
a higher incidence of grade ≥3 treatment- related AEs 
(58% vs 25%), respectively. Median OS was not reached 
with the triplet compared with 26.3 months with doublet 
and the 2- year OS rate was higher with the triplet (63% 
vs 52%). These data suggest a potential benefit with 
the triplet combination that will need to be confirmed 
with longer follow- up.83 84 In COMBI- i (NCT02967692), 
a phase III study of dabrafenib plus trametinib with or 
without spartalizumab (PD-1 inhibitor), results from 
the non- randomized part of the trial included an ORR 
of 78% and grade ≥3 treatment- related AEs in 72% of 
patients treated with the triplet therapy.85 While initial 
ORRs from some trials are high, no information has been 
reported regarding the durability of these responses and 
whether they will translate into an OS benefit relative to 
BRAF plus MEK inhibition or I- O agents alone, or with 
these approaches used in sequence. The generally high 
incidences of grade ≥3 AEs with triplet regimens is also a 
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Figure 3 Improving long- term survival in patients with metastatic melanoma. LDH, lactate dehydrogenase. (Figure from 
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for such trials may be nivolumab plus ipilimumab, which 
represents an alternative and possibly more powerful 
standard of care than the comparators used so far.
IMPemBra (NCT02625337) was a phase II study 
designed to evaluate several dabrafenib plus trametinib 
dosing schedules in combination with pembrolizumab.86 
Early results from this small trial suggest that intermittent, 
short- term administration of dabrafenib plus trametinib 
in combination with pembrolizumab may provide the 
efficacy benefits expected with triplet therapy while mini-
mizing both toxicity and the development of resistance.87 
Results have recently been presented from the single- arm, 
phase II TRIDeNT study (NCT02910700), which includes 
treatment with a combination of nivolumab, dabrafenib, 
and trametinib in patients with BRAF- mutant mela-
noma.88 Unlike other comparable trials, patients with 
disease that was refractory to previous PD-1 inhibitor 
therapy or those with brain metastases are eligible for 
inclusion. The incidence of grade 3 or 4 treatment- 
related AEs (65% of patients) was similar to those of 
other triplet trials. Efficacy data showed an ORR of 100% 
in PD-1 inhibitor- naive patients (including two CRs) 
and an ORR of 83% in patients with refractory disease 
(including one CR); ORRs were similar in patients with 
and without brain metastases (88%, including two CRs, 
in patients with brain metastases; 93%, including one CR, 
in those without). These data suggest that triplet therapy 
may have particular value, and merits further evaluation 
in patients with PD-1 inhibitor- refractory disease and/or 
those with brain metastases.
With the efficacy of triplet regimens still to be deter-
mined, a rational approach may be to use what is thought 
to be the most effective treatment first. Ongoing trials 
such as SECOMBIT, DREAMseq, and EBIN should ulti-
mately help to determine which sequence of I- O and 
targeted agents is most active for particular subsets of 
patients and whether using a PD-1 inhibitor with inter-
mittent or short- term targeted therapy is effective.
Other agents designed to target different components 
of the immune system or oncogenic processes/path-
ways are under evaluation, either alone or in combina-
tion with a PD-1 inhibitor. In the phase III LEAP-3 study, 
pembrolizumab is being evaluated in combination with 
lenvatinib, a multireceptor tyrosine kinase inhibitor, in 
previously untreated patients with advanced melanoma 
(NCT03820986).89 Another approach is to combine an 
I- O agent with a vaccine. A phase III trial (KEYNOTE-
034/MASTERKEY265/NCT02263508)90 designed to eval-
uate TVEC plus pembrolizumab was started after results 
from a phase Ib study showed that the vaccine followed 
by combination therapy gave a response rate of 62% in 
patients with advanced melanoma, with no dose- limiting 
toxicities reported.91
Agents are under evaluation that target other immune 
checkpoint receptors, such as lymphocyte- activation 
gene-3 (LAG-3; eg, relatlimab)92 and glucocorticoid- 
induced tumor necrosis factor receptor (GITR).93 A 
phase II/III study of relatlimab plus nivolumab versus 
nivolumab in patients with untreated metastatic unre-
sectable melanoma was initiated (NCT03470922)94 after 
phase I/IIa results showed responses with the combina-
tion in a heavily pretreated population of patients with 
melanoma and progression on prior anti- PD-1/anti- 
PD- L1 therapy. Data from this initial trial also showed 
that the combination had a safety profile similar to 
that of nivolumab monotherapy.92 Bempegaldesleukin 
is a pegylated IL-2 pathway agonist. In the phase I/II 
PIVOT-02 study, an ORR of 53% (34% CRs) was reported 
with first- line bempegaldesleukin plus nivolumab treat-
ment of patients with metastatic melanoma; responses 
were durable and were observed regardless of PD- L1 
expression and the combination was well tolerated.95 
Bempegaldesleukin plus nivolumab is now under evalua-
tion in a randomized phase III study in patients with previ-
ously untreated, unresectable, or metastatic melanoma 
(NCT03635983).96 Another approach involves using toll- 
like receptor-9 agonists to stimulate innate and adaptive 
antitumor immune responses. These agents, including 
tilsotolimod and CMP-001, are being studied in mela-
noma.97 98 A randomized, phase II trial with intradermal 
tilsotolimod in pT3-4 cN0M0 melanoma (INTRIM) is in 
progress (NCT04126876).99 Data from phase I studies 
showed acceptable tolerability and evidence of antitumor 
activity alone (intratumoral tilsotolimod) and in combi-
nation with pembrolizumab (CMP-001).97 98 Other agents 
are designed to target the tumor, although often with 
the goal of mediating immunomodulatory effects. These 
include entinostat, a histone deacetylase inhibitor that 
leads to the downregulation of immunosuppressive cell 
types in the tumor microenvironment.100 BMS-986179 is 
an anti- CD73 antibody that prevents the conversion of 
AMP to adenosine, with the goal of stopping adenosine- 
associated immunosuppression and tumor progres-
sion.101 Another approach involves inhibiting heat shock 
protein 90 (HSP90), for example, with XL888; preclinical 
data suggest that inhibiting HSP90 may help to overcome 
resistance to BRAF plus MEK inhibitor combinations.102
CONCLUSION
The potential for long- term survival in patients with 
metastatic melanoma is an important decision- making 
factor and, accordingly, associated outcomes need to 
be assessed appropriately and accurately. Metrics that 
encompass economic or QoL parameters may be partic-
ularly helpful in describing the long- term value of agents 
used to treat these patients. The current data indicate 
that several treatment approaches offer the potential for 
long- term survival. Combined CTLA-4 and PD-1 inhibitor 
immunotherapy results in the highest OS plateau (up to 
52% of patients), and in our opinion, may achieve long- 
term survival (functional cure) in the greatest number 
of patients. We propose that patients may be considered 
functionally cured if they have responded to treatment 
and have been off treatment for at least 2 years without 
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outcomes for those patients who do not experience long- 
term OS.
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